![](images/graphics/blank.gif)
Systemic therapy for hepatocellular carcinoma
-
Macroscopic vascular invasion (MVI) significantly impacts survival in patients with hepatocellular carcinoma (HCC), warranting systemic therapy over locoregional therapy. Despite novel approaches, HCC with MVI has a poor prognosis compared to early-to intermediate-stage HCC. This study aimed to evaluate the safety and efficacy of carbon-ion radiotherapy (C-ion RT) for HCC characterized by MVI.
9p
vishanshan
27-06-2024
2
1
Download
-
Novel immunotherapy combination therapies have improved outcomes for patients with hepatocellular carcinoma (HCC), but responses are limited to a subset of patients. Little is known about the inter- and intra-tumor heterogeneity in cellular signaling networks within the HCC tumor microenvironment (TME) that underlie responses to modern systemic therapy.
14p
vicwell
29-02-2024
6
2
Download
-
Historically, high hepatocellular carcinoma (HCC)–related mortality has been, in part, due to lack of effective therapies; however, several systemic therapies have been recently approved for HCC treatment, including regorafenib and ramucirumab. These two treatments utilize different routes of administration (four daily tablets and biweekly intravenous infusions, respectively) and have different risks of adverse events (AEs).
13p
vischultz
20-10-2023
2
1
Download
-
Although the standard therapy for advanced-stage hepatocellular carcinoma (HCC) is systemic chemotherapy, the combination of atezolizumab and bevacizumab (atezo+bev) with a high objective response rate may lead to conversion to resection in patients with initially unresectable HCC. This study aims to evaluate the efficacy of atezo+bev in achieving conversion surgery and prolonged progression-free survival (PFS) for initially unresectable HCC.
7p
vioracle
29-09-2023
5
2
Download
-
In hepatocellular carcinoma (HCC), locoregional therapy (LRT) included transarterial chemotherapy embolization - TACE is performed as a bridging or downstaging treatment, improved overall survival, or a curative treatment. Liver Imaging Reporting and Data Systems (LI-RADS) Treatment Response was created to evaluate each lesion post-TACE, which has localized and is suitable for determining whether the tumor is still viable or non-viable.
8p
vigamora
23-05-2023
5
2
Download
-
Patients with hepatocellular carcinoma (HCC) and Child–Pugh B liver cirrhosis have poor prognosis and are underrepresented in clinical trials. The CELESTIAL trial, in which cabozantinib improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with HCC and Child–Pugh A liver cirrhosis at baseline, was evaluated for outcomes in patients who had Child–Pugh B cirrhosis at Week 8.
10p
vikolindagrabar
27-07-2022
4
3
Download
-
To describe and analyze the predictive models of the prognosis of patients with hepatocellular carcinoma (HCC) undergoing systemic treatment. This study describes and analyzes the prognostic models developed and validated for patients with HCC who have undergone systemic treatment. The results show that there are some methodological flaws in the model development process, and that external validation is rarely performed.
17p
viangelamerkel
27-07-2022
8
4
Download
-
After liver resection (LR), patients with hepatocellular cancer (HCC) are at high risk of recurrence. There are no approved anti-cancer therapies known to affect such risk, highlighting the acute need for novel systemic therapies to control the probability of disease relapse.
9p
vianrose2711
27-04-2021
7
0
Download
-
A major challenge to the clinical utility of let-7 for hepatocellular carcinoma (HCC) therapy is the lack of an effective carrier to target tumours. We confirmed the high transfection efficiency of cholesterol-conjugated let-7a miRNA mimics (Chol-let-7a) in human HCC cells, as well as their high affinity for liver tissue in nude mice.
13p
vilisa271
22-09-2020
12
1
Download
-
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Advanced HCC has poor prognosis with short survival rate. According to Barcelona Classification of Liver Cancer (BCLC), systemic therapy is optimal treatment for patients at this stage. In 2007, the targeted therapy with sorafenib was first approved to treat advanced HCC, which helps prolong survival of the patients. This article aims: To update the findings and application of adjuvant regimens for HCC.
6p
angicungduoc7
09-09-2020
14
1
Download
-
epatocellular carcinoma (HCC) is the most common type of primary liver cancer. Advanced HCC has poor prognosis with short survival rate. According to Barcelona Classification of Liver Cancer (BCLC), systemic therapy is optimal treatment for patients at this stage. In 2007, the targeted therapy with sorafenib was first approved to treat advanced HCC, which helps prolong survival of the patients. This article aims: To update the findings and application of adjuvant regimens for HCC.
6p
kequaidan7
04-09-2020
14
2
Download
-
Despite advances in therapeutics, outcomes for hepatocellular carcinoma (HCC) remain poor and there is an urgent need for efficacious systemic therapy. Unfortunately, drugs that are successful in preclinical studies often fail in the clinical setting, and we hypothesize that this is due to functional differences between primary tumors and commonly used preclinical models.
10p
vimoscow2711
29-08-2020
16
2
Download
-
Approximately 20 % of hepatocellular carcinoma (HCC) patients diagnosed in the early stages may benefit from potentially curative ablative therapies such as surgical resection, transplantation or radiofrequency ablation. For patients not eligible for such options, prognosis is poor.
9p
vimale2711
25-08-2020
11
1
Download
-
The nomogram of the Barcelona Clinic Liver Cancer (BCLC) for hepatocellular carcinoma (HCC) has been used for outcome prediction. Patients with BCLC stage C HCC often undergo anti-cancer therapy against current treatment guidelines in real world practice.
9p
vibaku2711
22-07-2020
9
2
Download
-
TAE-gene therapy for hepatoma, incorporating the tumor-targeted therapeutic efficacy of trans-arterial embolization, hydroxyapatite nanoparticles (nHAP) and anti-cancer wild-type p53 gene (wt-p53), was presented in our former studies (Int J Nanomedicine 8:3757-68, 2013, Liver Int 32:998-1007, 2012).
17p
vikuala271
13-06-2020
20
2
Download
-
Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary P36 provides a detailed repository of the latest information regarding HCC epidemiology, diagnosis, imaging, pathology, staging, and treatment options.
10p
pretty26
10-12-2010
59
5
Download
-
Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary P41 provides a detailed repository of the latest information regarding HCC epidemiology, diagnosis, imaging, pathology, staging, and treatment options.
10p
pretty26
10-12-2010
65
5
Download
-
Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary P42 provides a detailed repository of the latest information regarding HCC epidemiology, diagnosis, imaging, pathology, staging, and treatment options.
10p
pretty26
10-12-2010
51
4
Download
-
Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary P40 provides a detailed repository of the latest information regarding HCC epidemiology, diagnosis, imaging, pathology, staging, and treatment options.
10p
pretty26
10-12-2010
46
4
Download
-
Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary P39 provides a detailed repository of the latest information regarding HCC epidemiology, diagnosis, imaging, pathology, staging, and treatment options.
10p
pretty26
10-12-2010
60
5
Download
CHỦ ĐỀ BẠN MUỐN TÌM
![](images/graphics/blank.gif)